AGIOS PHARMACEUTICALS, INC. Depreciation
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Depreciation of $5.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. depreciation for the quarter ending 2020-06-30 was $2.43M, a 19.39% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. depreciation for the quarter ending 2020-03-31 was $2.47M, a 23.39% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. depreciation for the quarter ending 2019-12-31 was $1.88M, a 3.25% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. depreciation for the quarter ending 2019-09-30 was $2.08M, a 15.86% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. depreciation for fiscal 2025 was $5.20M, a 8.77% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. depreciation for fiscal 2024 was $5.70M, a 13.64% decline from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. depreciation for fiscal 2023 was $6.60M, a 21.43% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. depreciation for fiscal 2022 was $8.40M, a 4.55% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $5.20M 10-K · filed 2026-02-12 | ||||
| 2024-12-31 | $5.70M 10-K · filed 2026-02-12 | ||||
| 2023-12-31 | $6.60M 10-K · filed 2026-02-12 | ||||
| 2022-12-31 | $8.40M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | $8.80M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $9.40M 10-K · filed 2023-02-23 | ||||
| 2020-06-30 | $2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $4.91M 10-Q · filed 2020-07-30 | $6.78M derived: sum of 3 quarters · filed 2022-02-24 | $8.86M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $2.47M 10-Q · filed 2020-04-30 | $4.35M derived: sum of 2 quarters · filed 2022-02-24 | $6.43M derived: sum of 3 quarters · filed 2022-02-24 | $8.47M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.96M derived: sum of 2 quarters · filed 2022-02-24 | $6.00M derived: sum of 3 quarters · filed 2022-02-24 | $8.00M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $4.12M derived: sum of 2 quarters · filed 2020-07-30 | $6.12M 10-Q · filed 2019-10-31 | $8.06M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $4.04M 10-Q · filed 2020-07-30 | $5.98M derived: sum of 3 quarters · filed 2021-02-25 | $7.78M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.00M 10-Q · filed 2020-04-30 | $3.94M derived: sum of 2 quarters · filed 2021-02-25 | $5.74M derived: sum of 3 quarters · filed 2021-02-25 | $7.48M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.74M derived: sum of 2 quarters · filed 2021-02-25 | $5.47M derived: sum of 3 quarters · filed 2021-02-25 | $7.20M 10-K · filed 2021-02-25 | $7.17M 10-K · filed 2019-02-14 |
| 2018-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.54M derived: sum of 2 quarters · filed 2019-10-31 | $5.26M 10-Q · filed 2019-10-31 | $6.88M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.46M 10-Q · filed 2019-08-01 | $5.09M derived: sum of 3 quarters · filed 2020-02-19 | $6.70M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-03-31 | $1.73M 10-Q · filed 2019-05-02 | $3.35M derived: sum of 2 quarters · filed 2020-02-19 | $4.96M derived: sum of 3 quarters · filed 2020-02-19 | $6.53M derived: sum of 4 quarters · filed 2020-02-19 | |
| 2017-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $3.24M derived: sum of 2 quarters · filed 2020-02-19 | $4.81M derived: sum of 3 quarters · filed 2020-02-19 | $6.40M 10-K · filed 2020-02-19 | $6.43M 10-K · filed 2018-02-14 |
| 2017-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $3.19M derived: sum of 2 quarters · filed 2018-11-01 | $4.78M 10-Q · filed 2018-11-01 | $6.50M derived: sum of 4 quarters · filed 2019-02-14 | |
| 2017-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $3.16M 10-Q · filed 2018-08-02 | $4.89M derived: sum of 3 quarters · filed 2019-02-14 | $6.32M derived: sum of 4 quarters · filed 2019-02-14 | |
| 2017-03-31 | $1.59M 10-Q · filed 2018-05-04 | $3.31M derived: sum of 2 quarters · filed 2019-02-14 | $4.75M derived: sum of 3 quarters · filed 2019-02-14 | $6.05M derived: sum of 4 quarters · filed 2019-02-14 | |
| 2016-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $3.16M derived: sum of 2 quarters · filed 2019-02-14 | $4.46M derived: sum of 3 quarters · filed 2019-02-14 | $5.71M 10-K · filed 2019-02-14 | |
| 2016-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $2.74M derived: sum of 2 quarters · filed 2017-11-01 | $3.99M 10-Q · filed 2017-11-01 | $5.13M derived: sum of 4 quarters · filed 2018-02-14 | |
| 2016-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.55M 10-Q · filed 2017-08-08 | $3.69M derived: sum of 3 quarters · filed 2018-02-14 | $4.74M derived: sum of 4 quarters · filed 2018-02-14 | |
| 2016-03-31 | $1.25M 10-Q · filed 2017-05-04 | $2.39M derived: sum of 2 quarters · filed 2018-02-14 | $3.44M derived: sum of 3 quarters · filed 2018-02-14 | $4.22M derived: sum of 4 quarters · filed 2018-02-14 | |
| 2015-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $2.19M derived: sum of 2 quarters · filed 2018-02-14 | $2.97M derived: sum of 3 quarters · filed 2018-02-14 | $3.34M 10-K · filed 2018-02-14 | |
| 2015-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.83M derived: sum of 2 quarters · filed 2016-11-03 | $2.20M 10-Q · filed 2016-11-03 | $2.56M derived: sum of 4 quarters · filed 2017-02-16 | |
| 2015-06-30 | $780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $1.15M 10-Q · filed 2016-08-08 | $1.51M derived: sum of 3 quarters · filed 2017-02-16 | $1.86M derived: sum of 4 quarters · filed 2017-02-16 | |
| 2015-03-31 | $370.00K 10-Q · filed 2016-05-09 | $732.00K derived: sum of 2 quarters · filed 2017-02-16 | $1.08M derived: sum of 3 quarters · filed 2017-02-16 | $1.41M derived: sum of 4 quarters · filed 2017-02-16 | |
| 2014-12-31 | $362.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $708.00K derived: sum of 2 quarters · filed 2017-02-16 | $1.03M derived: sum of 3 quarters · filed 2017-02-16 | $1.37M 10-K · filed 2017-02-16 | |
| 2014-09-30 | $346.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $673.00K derived: sum of 2 quarters · filed 2015-11-06 | $1.00M 10-Q · filed 2015-11-06 | $1.34M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $327.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $659.00K 10-Q · filed 2015-08-07 | $999.00K derived: sum of 3 quarters · filed 2016-02-26 | $1.38M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | $332.00K 10-Q · filed 2015-05-11 | $672.00K derived: sum of 2 quarters · filed 2016-02-26 | $1.05M derived: sum of 3 quarters · filed 2016-02-26 | $1.42M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2013-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $717.00K derived: sum of 2 quarters · filed 2016-02-26 | $1.09M derived: sum of 3 quarters · filed 2016-02-26 | $1.44M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $377.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $751.00K derived: sum of 2 quarters · filed 2014-11-07 | $1.10M 10-Q · filed 2014-11-07 | $1.42M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $723.00K 10-Q · filed 2014-08-07 | $1.05M derived: sum of 3 quarters · filed 2015-02-24 | $1.36M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $349.00K 10-Q · filed 2014-05-09 | $672.00K derived: sum of 2 quarters · filed 2015-02-24 | $991.00K derived: sum of 3 quarters · filed 2015-02-24 | ||
| 2012-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $642.00K derived: sum of 2 quarters · filed 2015-02-24 | $1.18M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | $319.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $856.00K 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | $537.00K 10-Q · filed 2013-09-05 | ||||
| 2011-12-31 | $801.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |